Regeneron Pharmaceuticals Melanoma Trial Misses Primary PFS Goal
TARRYTOWN, New York, May 15, 2026 Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the...
melanoma
Advertisement
Phio Pharmaceuticals Showcases PH-762 Skin Cancer Trial Progress
KING OF PRUSSIA, Pa., May 12, 2026 Phio Pharmaceuticals announced that company leadership will participate in a virtual fireside...
Medicenna Advances MDNA11 Melanoma Trial in Italy
TORONTO, Ontario, May 13, 2026 Medicenna Therapeutics announced that the first patient has been enrolled and dosed in the...
Merck Unveils Major Oncology Advances at ASCO 2026
RAHWAY, N.J., May 12, 2026 Merck announced a major expansion of its oncology research portfolio ahead of the 2026...
Diakonos Gains FDA Fast Track for DOC1021 Melanoma
HOUSTON, May 6, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, has announced that...
Advertisements
Replimune RP1 Melanoma Drug Faces FDA Rejection
Woburn, Massachusetts | April 10, 2026 Replimune Group Inc. has announced that the U.S. Food and Drug Administration (FDA)...
FDA Clears Scancell IND for Phase 3 iSCIB1+ Melanoma Trial
Cambridge, United Kingdom, January 26, 2026 — Scancell Holdings plc announced on January 26, 2026, that the U.S. Food...
Bio-Techne and Nucleai Advance AI Spatial Biology to Unlock Melanoma Biomarkers
MINNEAPOLIS, USA, and TEL AVIV, Israel, November 4, 2025 — Bio-Techne Corporation (NASDAQ: TECH) and Nucleai, an AI-driven precision-medicine...
FDA Grants Fast Track Status to Werewolf Therapeutics’ Cancer Drug
WATERTOWN, Mass., October 8, 2025 — Werewolf Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
Advertisement
